| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Gaubius Institute TNO, P. O. Box 612, 2300 AP Leiden [P. H. A. Q., R. T. J. v. L., J. H. V.], and Department of Gastroenterology and Hepatology, University Hospital, Leiden [H. W. V.], The Netherlands
In 22 human tumor cell lines the regulation of production of plasminogen activators urokinase (u-PA) and tissue-type (t-PA) and their inhibitors PAI-1 and PAI-2 was studied. These four components may determine the net plasminogen activator activity, which is often associated with tumor development and metastatic processes. The amount of specific mRNA and protein produced by the cells was measured for all four components.
The frequent finding of t-PA (alone or in combination with u-PA) suggests that t-PA can also be a tumor-associated plasminogen activator. In 11 of the 22 cells PAI-1 mRNA and in 6 of the 22 cells PAI-2 mRNA was found, pointing to a possible role of plasminogen activator inhibitors in the tumor-related plasminogen activator activity.
This study demonstrates that there are at least two important regulatory steps in the regulation of production of plasminogen activators and their inhibitors: (a) the regulation at the mRNA level, since a high protein amount is always correlated with a high mRNA amount found in the tumor cells; (b) there must be a significant regulatory step at the (post)translational level as can be concluded from differences in mRNA usage.
1 To whom requests for reprints should be addressed.
Received 4/24/89. Revised 9/ 7/89. Revised 11/22/89. Accepted 12/ 4/89.
This article has been cited by other articles:
|
|
 |
|
  S. Rosmann, D. Hahn, D. Lottaz, M.-N. Kruse, W. Stocker, and E. E. Sterchi Activation of Human Meprin-alpha in a Cell Culture Model of Colorectal Cancer Is Triggered by the Plasminogen-activating System J. Biol. Chem., October 18, 2002; 277(43): 40650 - 40658. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Vakili, L. Standker, M. Detheux, G. Vassart, W.-G. Forssmann, and M. Parmentier Urokinase Plasminogen Activator and Plasmin Efficiently Convert Hemofiltrate CC Chemokine 1 into Its Active [9-74] Processed Variant J. Immunol., September 15, 2001; 167(6): 3406 - 3413. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mazumdar, L. Adam, D. Boyd, and R. Kumar Heregulin Regulation of Urokinase Plasminogen Activator and its Receptor: Human Breast Epithelial Cell Invasion Cancer Res., January 1, 2001; 61(1): 400 - 405. [Abstract] [Full Text]
|
|
|
|
|
|
V. Nienaber, J. Wang, D. Davidson, and J. Henkin Re-engineering of Human Urokinase Provides a System for Structure-based Drug Design at High Resolution and Reveals a Novel Structural Subsite J. Biol. Chem., March 15, 2000; 275(10): 7239 - 7248. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. H. A. Quax, J. M. Grimbergen, M. Lansink, A. H. F. Bakker, M.-C. Blatter, D. Belin, V. W. M. van Hinsbergh, and J. H. Verheijen Binding of Human Urokinase-Type Plasminogen Activator to Its Receptor : Residues Involved in Species Specificity and Binding Arterioscler. Thromb. Vasc. Biol., May 1, 1998; 18(5): 693 - 701. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.N. Raghunath, J. E. Tomaszewski, S. T. Brady, R. J. Caron, S. S. Okada, and E. S. Barnathan Plasminogen Activator System in Human Coronary Atherosclerosis Arterioscler. Thromb. Vasc. Biol., September 1, 1995; 15(9): 1432 - 1443. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
